

## Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

Yoshihiro Tanaka<sup>1</sup> · Kazuhiro Yoshida<sup>1</sup> · Atsuko Yamada<sup>1</sup> · Toshiyuki Tanahashi<sup>1</sup> · Naoki Okumura<sup>1</sup> · Nobuhisa Matsuhashi<sup>1</sup> · Kazuya Yamaguchi<sup>1</sup> · Tatsuhiko Miyazaki<sup>2</sup>

Published online: 25 April 2016  
© Springer-Verlag Berlin Heidelberg 2016

**Erratum to: Cancer Chemother Pharmacol**  
**DOI 10.1007/s00280-016-2985-y**

Unfortunately, the online published article has error in Table 5. The correct Table 5 is given here. The original article has been corrected.

---

The online version of the original article can be found under doi:[10.1007/s00280-016-2985-y](https://doi.org/10.1007/s00280-016-2985-y).

---

✉ Yoshihiro Tanaka  
yoshihirotana11@hotmail.com

<sup>1</sup> Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan

<sup>2</sup> Department of Pathology, Gifu University Hospital, Gifu, Japan

**Table 5** Docetaxel, CDDP, and 5-Fu for advanced esophageal cancer

References (first author)	Target	Regimen ( $m^2$ )	Phase	Cases, <i>n</i>	Grade 3/4 leukopenia (%)	Grade 3/4 neutropenia (%)	Febrile neutropenia (%)	Response rate (%)	Histopathological response rate (>grade 2) (%)	Histopathological complete response rate (grade 3) (%)	Dose reduction rate in the second cycle (%)	Protocol completion rate (%)
Takahashi [32]	Esophageal cancer (SCC) Stages III, IV	D: 50 (day 1) C: 70 (day 1) F: 700 (days 1–5)/3 wks	I/II	39	53.8	43.6	12.8	66.6	–	–	–	–
Osaka [33]	Esophageal cancer (SCC) Stages III, IV	D: 60 (day 1) C: 60 (day 1) F: 800 (days 1–5)/3–4 wks × 2 courses	II	30	33.3	–	–	83.3 (primary lesion)	–	–	–	96.7
Yamasaki [23]	Esophageal cancer (SCC) Stages III, IV	D: 70 (day 1) C: 70 (day 1) F: 700 (days 1–5)/3 wks × 2 courses	I/II	9/40	72.5	90	10	72.5	40	25	–	82.5
Tamura [34]	Esophageal cancer (SCC) Stage IV	D: 60 (day 1) C: 70 (day 1) F: 600 (days 1–5)/4 wks × 2 courses	II	29	52	76	21	34.5 (confirmed cases)	–	–	13.8	–
Ferri [35]	Esophageal cancer and gastric cancer (AD) Stages II, III, IV	D: 75 (day 1) C: 75 (day 1) F: 750 (days 1–5)/3 wks × 3 courses	II	43	–	20	2.3	–	–	9.8	–	95
Hara [36]	Esophageal cancer (SCC) Stages II, IIB, III	D: 70 (day 1) C: 70 (day 1) F: 750 (days 1–5) D: 75 (day 1) C: 75 (day 1) F: 750 (days 1–5)/3 wks × 3 courses	II	42	45.2	83.3	2.4	64.3	51	17	64.3	95.2
Watanabe [37]	Esophageal cancer (SCC, AD) Stages IIB, III, IVA, IVB (TNM6)	D: 60 (day 1) C: 6 (days 1–5) F: 350 (days 1–5)/3 wks × 2 courses	Prospective intention-to-treat	50	–	78.2	14.5	53.7	26	12	–	–

Table 5 continued

References (first author)	Target	Regimen (m <sup>2</sup> )	Phase	Cases, <i>n</i>	Grade 3/4 leukopenia (%)	Grade 3/4 neutropenia (%)	Febrile neutropenia (%)	Response rate (%)	Histopathological response rate (>grade 2) (%)	Histopathological complete response rate (grade 3) (%)	Dose reduction rate in the second cycle (%)	Protocol completion rate (%)
Hironaka [38]	Esophageal cancer (SCC, AS, B)	D: 30 (days 1, 15) C: 80 (day 1) F: 800 (days 1–5)/4 wks	I/II	10/52	9.1	25.5	0	62	–	–	–	–
Current study	Esophageal cancer (SCC) Stages II, III	D: 35 (days 1, 15) C: 40 (days 1, 15) F: 400 (days 1–5, 15–19)	II	32	12.5	31.3	0	90.3	53.2	21.9	0	100

SCC squamous cell carcinoma, AD adenocarcinoma, A5 adenosquamous carcinoma, B basaloid carcinoma, D docetaxel, C cisplatin, F fluorouracil